BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 89   

Articles published

BCRX 11.17
price chart
Insider Trade: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)'s Senior Vice ...
Thomas Staab is the Senior Vice President and CFO of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) 11.32 +0.04 0.35% .
BioCryst Pharmaceuticals CFO Sells $33000.00 in Stock (BCRX)  Dakota Financial News
BioCryst Pharmaceuticals CFO Thomas R. Staab II Sells 3000 Shares (BCRX)  The Legacy
Stock Update - BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed the last trading session at 11.28. In the current trading session the stock reached as high as 11.45 and dipped down to 11.19.
Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a predominantly clinical-stage biotech company focused on developing novel small molecule drugs to treat varying diseases, scorched higher by as much as 12% in Wednesday's trading session ...
Durham's BioCryst gets $35M federal contract for Ebola treatment  Triangle Business Journal
Ebola Finances Coming Back in the News  24/7 Wall St.
BofA: We're Upgrading Biocryst Pharmaceuticals
In a report published Monday, analysts at Bank of America upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) to Neutral.
BioCryst Pharmaceuticals Upgraded to "Neutral" at Bank of America ...  Dakota Financial News
BioCryst Upgrade Almost Looks Misunderstood  24/7 Wall St.
Review on Stocks On The Dive - BioCryst Pharmaceuticals, Inc. (NASDAQ ...
On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: BioCryst Pharmaceuticals, Inc.
Yarlagadda S. Babu Sells 12105 Shares of BioCryst Pharmaceuticals Stock ...  WKRB News
Investors Dumping 4 Biotech Stocks - Intrexon (XON), Idera Pharmaceuticals ...  Wall Street Observer
Stock Analysis on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[Globe Newswire] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)(TREND ANALYSIS) announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's development programs at the 14th Annual Needham ...
BioCryst Pharmaceuticals Receives $16.12 Consensus Target Price from ...  Mideast Time
Stock Insight: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of ...
Buzz Stocks: Charter Communications, Inc., BioCryst Pharmaceuticals, Inc., and ...
U.S. benchmarks are poised to pare a portion of yesterday's massive gains, with futures pointed lower on the last day of the first quarter.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a Buy: Needham
In a research note issued to investors, Serge Belanger at Needham Reiterated their Buy rating on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The analyst placed a $15.00 price target on the stock which indicates a 53.69% upside to the last closing ...
Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
BioCryst Pharmaceuticals PT Set at $15.00 by Needham & Company LLC (BCRX)  Dakota Financial News